# 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

> **NCT02624700** · PHASE2 · TERMINATED · sponsor: **Virginia Commonwealth University** · enrollment: 13 (actual)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer
- Recurrent Breast Cancer

## Interventions

- **DRUG:** Experimental Arm A: Pemetrexed
- **DRUG:** Experimental Arm A: Sorafenib
- **DRUG:** Experimental Arm B: Pemetrexed
- **DRUG:** Experimental Arm B: Sorafenib

## Key facts

- **NCT ID:** NCT02624700
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01-28
- **Primary completion:** 2019-07-10
- **Final completion:** 2019-07-10
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2020-07-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02624700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02624700, "2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02624700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*